 This randomized, double-blind, controlled, outpatient two-period, two-treatment crossover study is designed to evaluate the efficacy and safety of amifampridine phosphate in patients ages 2 and above diagnosed with certain genetic subtypes of CMS and demonstrated open label amifampridine phosphate or history of sustained amifampridine benefit from treatment. 